XTalks

JUNE 14, 2022

Although seldom associated with human disease, it can lead to severe or life-threatening adverse events — such as bacteremia/sepsis, pneumonia, invasive fungal rhinosinusitis, or disseminated fungal infection — in immunocompromised individuals.

Contamination 52

Contamination Bacterium Bacteria Branding 52

XTalks

NOVEMBER 6, 2020

DNA vaccines designed using the platform consist of a combination of an advanced gene expression plasmid (pDNA) with gene(s) of interest, and a probiotic bacterium to deliver the vaccine directly to the gut, where it binds to intestinal epithelial cells.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

JULY 28, 2021

Compared to Vaxneuvance’s targeting of 15 different strains of the bacterium, Pfizer’s shot protects against 20. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis. This is seven more strains than its current winning vaccine Prevnar 13, which registered $5.95

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

Pharma in Brief

NOVEMBER 20, 2023

The substances listed in Schedule 1 include amino acids, certain vitamins, and “[a] plant or a plant material, an alga, a bacterium, a fungus or a non-human animal material”.

Production 52

Production Cosmetics Regulation Branding 52

XTalks

JULY 25, 2023

Kelly Warfield, Emergent’s senior vice president, science and development, in the company’s press release. Anthrax is a rare, yet severe disease caused by the bacterium B. What Is Anthrax? anthracis , primarily affecting livestock and wild game.

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

XTalks

JANUARY 20, 2021

To test their hypothesis in the lab, the researchers infected mice with a stomach bacterium and fed them a protein found in egg white called ovalbumin at the same time (this protein is commonly used as a typical model food antigen in experiments).

Immune Response 52

Immune Response Research Allergies Protein 52

XTalks

AUGUST 2, 2023

With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. 21) Merck KGaA By: Ayesha Rashid, Ph.D.

Sales 98

Sales Manufacturing FDA Approval Life Science 98